Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translational assessment instruments for preclinical to first-in-human decision-making: a scoping review.

Journal of translational medicine·2026
Same author

A survey to evaluate animal methods bias experienced by India-based researchers in the peer review of manuscripts and grant applications.

NAM journal·2026
Same author

Data-driven science, ethics and risk: Building knowledge of key ethics-risk intersections relevant to public sector decision-making.

Alternatives to laboratory animals : ATLA·2026
Same author

Defining key criteria for microhaplotype locus selection in forensic genetics: Progress and recommendations by the Microhaplotype Working Group.

Forensic science international. Genetics·2026
Same author

Beyond the amyloid hypothesis: leveraging human-centered complex <i>in vitro</i> models to decode Alzheimer's disease etiology.

Frontiers in toxicology·2026
Same author

Evaluating the translational value of preclinical models: Available tools and frameworks, challenges and strategies.

Alternatives to laboratory animals : ATLA·2025

Related Experiment Video

Updated: Apr 3, 2026

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.9K

A Human-Based Integrated Framework for Alzheimer's Disease Research.

Francesca Pistollato, Sarah E Cavanaugh, P Charukeshi Chandrasekera

    Journal of Alzheimer'S Disease : JAD
    |September 25, 2015
    PubMed
    Summary

    Animal models fail to translate Alzheimer's disease (AD) research into human therapies. Shifting to human-based methods, including cellular and computational models, is crucial for developing effective AD treatments.

    Keywords:
    Alzheimer’s diseaseanimal modelsbiomarkerscomputational methodshuman-based methodsrisk factorsstem cellstranslational gap

    More Related Videos

    Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
    09:47

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

    Published on: December 15, 2023

    2.0K
    Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
    09:38

    Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

    Published on: November 14, 2017

    15.8K

    Related Experiment Videos

    Last Updated: Apr 3, 2026

    Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
    06:46

    Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

    Published on: August 4, 2018

    12.9K
    Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
    09:47

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

    Published on: December 15, 2023

    2.0K
    Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
    09:38

    Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

    Published on: November 14, 2017

    15.8K

    Area of Science:

    • Neuroscience
    • Genetics
    • Epidemiology

    Background:

    • Decades of Alzheimer's disease (AD) research using animal models have yielded limited therapeutic success.
    • A significant translational gap exists between animal model findings and human patient outcomes.
    • Over-reliance on non-human models and underutilization of human-relevant methods contribute to this failure.

    Purpose of the Study:

    • To propose a paradigm shift from animal-based to human-based research methods for Alzheimer's disease.
    • To identify strategies for overcoming translational barriers in AD drug development.
    • To enhance the elucidation of AD pathogenesis and the design of effective treatments.

    Main Methods:

    • Utilizing human-based cellular and computational models.
    • Integrating epidemiological and clinical studies.
    • Analyzing disease processes at multiple levels: gene expression, protein levels, cellular, tissue/organ, individual, and population.

    Main Results:

    • Human-based methods offer a more accurate approach to understanding AD.
    • Novel cellular and computational models facilitate human-relevant data acquisition.
    • A multi-level analysis provides a comprehensive view of AD pathogenesis.

    Conclusions:

    • A paradigm shift toward human-based research is essential for advancing Alzheimer's disease understanding and treatment.
    • Human-based approaches are critical for developing effective therapeutic and preventive strategies.
    • This shift is imperative given the rising prevalence of AD.